Empatica Achieves CE MDR Certification for EpiMonitor, Bringing Round-the-Clock Epilepsy Monitoring to Europe
"We didn't want to make just another health tracker, but to provide a lifeline for the millions of people living with epilepsy around the world." Simone Tognetti, Empatica's CTO & Co-founder
Share
EpiMonitor comprises the sophisticated EmbracePlus watch and a companion smartphone app. EpiMonitor's algorithm continuously analyzes user data, looking for patterns that may resemble a generalized tonic-clonic seizure, and sends automated alerts to caregivers with scientifically proven 98% accuracy. EpiMonitor also offers a detailed sleep, activity, and seizure diary, providing people with epilepsy and their doctors with important information to make empowered decisions on their health journey.
EpiMonitor is now available in Germany, France, Italy, Spain, Denmark, Sweden, Belgium, Luxembourg, Austria, Liechtenstein, Ireland, the Netherlands, Malta, and Finland. The EpiMonitor app is also available in all local languages for a seamless experience for its users.
'EpiMonitor's availability in Europe is a great milestone for the epilepsy community,' said Simone Tognetti, Empatica's CTO & Co-founder. 'Our goal is to continue bringing technology that improves lives to more people around the world. EpiMonitor is the world's only non-invasive, medical-grade wearable for night and day epilepsy monitoring, and our rigorous engineering methods and quality processes guarantee unmatched safety and accuracy. With EpiMonitor, we have taken the best of our previous wearables and amplified it in a solution that uses our most innovative and powerful technology, alongside algorithms that provide detailed and meaningful health insights. We didn't want to make just another health tracker, but to provide a lifeline for the millions of people living with epilepsy around the world.'
Key features of EpiMonitor include:
Fully medical-grade technology consisting of a wearable and app
Automatic generalized tonic-clonic seizure detection and alerts to caregivers (98% accuracy; low False Alarm Rate)
Ability for users to send self-triggered alerts to caregivers
Up to 7 days of battery life
A user-friendly mobile app with a detailed, automated diary
Daily sleep and activity tracking through Empatica's algorithms
Detailed reports that can be exported and shared with a doctor
High accessibility with app translations in 8 languages
Compatibility with iOS and Android smartphones
Empatica has been the market leader in providing the world's only medical watches for people living with epilepsy for nearly a decade. Epilepsy affects 6 million people in Europe, with approximately 15% of those being children. Studies indicate that up to 40% of epilepsy cases are difficult to treat, and a third of people with epilepsy are refractory to current medications. Sudden Unexpected Death in Epilepsy (SUDEP) is the number one cause of epilepsy-related deaths in people with pharmacoresistant epilepsy. Most SUDEP deaths occur when a generalized tonic-clonic seizure occurs during sleep.
EpiMonitor can be purchased directly from the Empatica website. To learn more visit empatica.com/epimonitor.
Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. In 2018, Empatica's Embrace wearable received FDA clearance for seizure monitoring, making it the world's first epilepsy watch to be cleared by the FDA. Its successor, EpiMonitor, launched in the US in 2024 after receiving FDA clearance. Empatica's flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and NASA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
27 minutes ago
- Newsweek
The Bulletin June 21, 2025
The rundown: The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country. Find out what steps are being taken. Why it matters: In April, the Food and Drug Administration (FDA) said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. Read more in-depth coverage: Over 300 Animals Removed From US Safari After Decade of Red Flags TL/DR: Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing. What happens now? A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients.' Deeper reading How Animal Testing in US Could Be Transformed Under Trump
Business Wire
an hour ago
- Business Wire
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model
ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. AC102 regenerates connections between the inner ear and auditory nerve in a preclinical model and eliminates tinnitus. Efficacy of AC102 on sudden hearing loss and tinnitus currently investigated in clinical trial. Share In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, they nearly disappeared in the AC102 group after five weeks – in clear contrast to the placebo group. Additionally, the AC102 group showed significantly less loss of synaptic connections between the inner ear and the auditory nerve than the placebo group. This damage is considered to be a potential cause of tinnitus: 'Our results suggest regeneration of inner ear structures that are critical for tinnitus and could be an important milestone and a glimmer of hope for a causal treatment of tinnitus,' says the study's first author, Dr. Konstantin Tziridis from Erlangen University Hospital. About two-thirds of sudden hearing loss patients also suffer from tinnitus, which persists in around 30% of cases. Although 10-15% of adults experience tinnitus, no effective causal treatment exists. AC102 has the potential to become a new treatment option. In a preclinical acoustic trauma model, it almost completely reversed sudden hearing loss. Since tinnitus often accompanies sudden hearing loss, AudioCure is investigating AC102's potential efficacy also against tinnitus in its ongoing study. AudioCure's CEO, Dr. Reimar Schlingensiepen, emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients and doctors who have no approved drug treatment available at present." AC102 has already been tested for safety and tolerability in a clinical study and is currently being examined in a Europe-wide Phase-2-study in patients for its effectiveness in sudden hearing loss and tinnitus.
Business Wire
an hour ago
- Business Wire
CoStar Group Names Alexa-Maria Rathbone Barker as Head of CoStar for Europe
LONDON--(BUSINESS WIRE)--CoStar Group (NASDAQ: CSGP), a global leader in commercial real estate information, analytics, online marketplaces and 3D digital twin technology, today announced the appointment of Alexa-Maria Rathbone Barker as Head of CoStar Europe. This leadership elevation comes as part of the company's strategic growth plan across Europe. In her expanded role, Alexa will oversee CoStar's operations in the UK, reaffirming the company's position as the most trusted provider of real-time, verified commercial real estate (CRE) intelligence. Her responsibilities will include deepening CoStar's relationships with key players in the CRE space - especially among agencies - and helping clients grow through collaboration and partnerships. Beyond her UK remit, Alexa will also lead CoStar's European expansion. With product launches planned in France, Spain, and Germany, her multilingual skills and pan-European expertise will be instrumental in driving growth and building CoStar's footprint in new markets. Alexa joined CoStar Group as Head of European Sales, where over the past three years she led sales strategy and execution for the company's market-leading platforms across the UK and Europe. Prior to that, she spent a decade at Bloomberg, holding senior leadership positions focused on international growth and heading the European Analytics team. Fluent in English, French, and Spanish, Alexa brings a rare combination of extensive product knowledge, insight, regional expertise, and cross-cultural fluency to her new position. 'Alexa's extensive experience, deep knowledge of the CRE landscape, and her clear understanding of our clients' evolving needs make her the ideal choice to lead CoStar's efforts across the UK and Europe,' said Robin Rossmann, Managing Director, Europe at CoStar Group. 'Her promotion is a testament to our ongoing commitment to cultivating talent and delivering world-class services to our clients.' About CoStar Group, Inc. CoStar Group (NASDAQ: CSGP) is a global leader in commercial real estate information, analytics, online marketplaces and 3D digital twin technology. Founded in 1986, CoStar Group is dedicated to digitizing the world's real estate, empowering all people to discover properties, insights, and connections that improve their businesses and lives. CoStar Group's major brands include CoStar, a leading global provider of commercial real estate data, analytics, and news; LoopNet, the most trafficked commercial real estate marketplace; the leading platform for apartment rentals; and the fastest-growing residential real estate marketplace. CoStar Group's industry-leading brands also include Matterport, a leading spatial data company whose platform turns buildings into data to make every space more valuable and accessible, STR, a global leader in hospitality data and benchmarking, Ten-X, an online platform for commercial real estate auctions and negotiated bids and OnTheMarket, a leading residential property portal in the United Kingdom. CoStar Group's websites attracted over 130 million average monthly unique visitors in the first quarter of 2025, serving clients around the world. Headquartered in Arlington, Virginia, CoStar Group is committed to transforming the real estate industry through innovative technology and comprehensive market intelligence. From time to time, we plan to utilize our corporate website as a channel of distribution for material company information. For more information, visit
